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1. Introduction  
Hepatocellular carcinoma is one of the most common malignancies worldwide, and its 
incidence is growing in association with viral and nonviral chronic liver diseases (Sherman 
M, 2010). Hepatocellular carcinoma is a lethal cancer, and improved survival relies on the 
detection of early tumors smaller then 2 cm, which are less likely to have dissemination (Di 
Tommaso, 2011). The diagnosis of hepatocellular carcinoma is based on a multidisciplinary 
approach, including imaging modalities and serum markers, such as alphafetoprotein (Zhou 
L  2006). However, such diagnosis still rests on the incontrovertible histological evidence 
obtained by CT scan or echo-guided needle biopsy. Radiology is the main technique used to 
detect hepatocellular carcinoma in the setting of cirrhosis; the typical imaging shows 
hepatocellular carcinoma bigger then 2 cm in more than 90% of cases. When the radiological 
features of hepatic liver nodules in cirrhosis are not typical, the American Association for 
the Study of Liver Diseases (AASLD) guidelines recommend the use of liver biopsy. The 
potential risks of bleeding and seeding due to liver biopsy can be minimized with very thin, 
20- to 21-gauge needles, so this invasive technique is recommended now and will be 
recommended in the future for approximately 50% of dubious hepatic nodules between 1 
and 2 cm in size. Indeed, the cumulative experience of several internationally recognized 
hepatology centers (Bolondi L, 2005)(Forner A, 2008)(Sangiovanni A, 2010)(Leoni S, 2010) 
has shown that 30% of 1 to 2 cm nodules are not malignant. Recently, Leoni et al. have 
reported that the application of international guidelines, even with three imaging 
techniques, leads to a false-negative rate of 20% for nodules ultimately shown to be 
hepatocellular carcinoma (Leoni S, 2010), whereas Sangiovanni et al. (Sangiovanni A, 2010) 
have documented in a single-technique scenario that 55% of patients will need to undergo 
biopsy for a final diagnosis. Thus, biopsy has a very crucial role when radiology fails and 
pathologists are asked to document malignancies in lesions that are also the most difficult to 
ascertain (Sherman M, 2010). Regarding the application of needle biopsy for small  liver 
nodules, the American Association for the Study of Liver Diseases recommends that biopsy 
should be performed for nodules less than 2 cm if their radiologic findings are not 
characteristic of hepatocellular arcinoma, whereas biopsy is not needed for lesions showing 
characteristic radiologic findings (Bruix J, 2005). This recommendation has been supported 
by prospective validation (Forner A, 2008) (Bruix J, 2011). Core liver biopsy is definitely 
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superior to fine needle aspiration, because the specimen obtained is suitable for the 
assessment of both architectural and cytologic features. Furthermore, the tissue block 
obtained provides materials for marker studies. Fine needle aspiration is usually adequate 
for the evaluation of large lesions that are likely to be moderately to poorly differentiated, 
where diagnostic criteria are easier to evaluate (ICGHN, 2009). An International Working 
Party of the World Congresses of Gastroenterology proposed a consensus nomenclature and 
diagnostic criteria for hepatocellular nodular lesions (International Working Party, 1995). 
The International Working Party classified nodular lesions found in chronic liver disease 
into large regenerative nodule, low-grade dysplastic nodule, high-grade dysplastic nodule, 
and hepatocellular carcinoma; this nomenclature has been widely adopted. In addition, the 
International Working Party introduced the concept of dysplastic focus as a cluster of 
hepatocytes with features of early neoplasia (in particular small cell change or iron-free foci 
in a siderotic background) measuring less than 0.1 cm, and defined small hepatocellular 
carcinoma as a tumor measuring less than 2 cm (International Working Party, 1995). More 
recent studies support the division of small hepatocellular carcinoma into two clinico-
pathological groups that have been termed early hepatocellular carcinoma and progressed 
hepatocellular carcinoma. Early hepatocellular carcinoma has a longer time to recurrence 
and a higher 5-year survival rate compared with progressed hepatocellular carcinoma 
(ICGHN, 2009).  
2. Morphological features 
The histological appearance of hepatocellular carcinoma has been described in detail over 
the years and criteria for diagnosis and nomenclature have been clarified (Lopez JB 2005). 
Distinct morphological features have been reported and, in the majority of cases, 
hepatocellular can be identified by routine haematoxylin-eosin stained sections, that show a 
malignant lesion with evidence of hepatocellular differentiation (ICGHN, 2009). The 
hepatocellular carcinoma’s cells are variably similar to the normal liver cells, depending on 
the degree of differentiation (Ishak KG, 2001). The nuclei are usually hyperchromic and 
irregular with prominent nucleoli and a high nuclear/cytoplasmic ratio. The tumor cells 
usually have distinct cell membranes and a moderate amount of eosinophilic, finely 
granular cytoplasm and may contain a variety of cellular products, mimicking normal and 
pathologic liver cell function (Goodman ZD, 2007). The cytoplasm could give a clear cell 
appearance due to the presence of cytoplasmic fat and/or glycogen. Cytoplasmic Mallory 
bodies and hyaline globules, representing alpha-1-antitrypsin storage, lightly eosinophilic 
ground-glass-like cytoplasmic inclusions, due to fibrinogen and other plasma proteins can 
be found. Bile pigment may be present in tumor cells or in dilated canaliculi, that can be 
easily observed even in hematoxylin eosin stained sections (Goodman ZD, 2007). The cells of 
hepatocellular carcinoma generally try to grow in ways that mimic the cell plates of normal 
liver, producing well-recognized growth trabecular pattern (Ishak KG, 2001). The 
histological picture could remember the early architecture of embryonic and foetal liver (fig. 
1), suggesting the hypothesis that carcinogenesis follows liver developing ontogenesis. The 
architectural feature show different growth patterns. Most often the tumor grows in a 
trabecular pattern with thickened cords of cells separated by vascular sinusoids, mimicking 
the cell plates and sinusoids of normal liver; a rapid growth of the tumor cells causes the 
plates to become thickened and contorted, producing trabeculae that are surrounded by 
endothelial cells. The trabeculae may contain very dilated canaliculi, producing a  
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Human embryonic liver at 8 weeks of 
gestation. 
 
The trabecular pattern 
The pseudoglandular pattern 
 
The solid pattern 
Fig. 1. The architecture of a human embryonic liver at 8 weeks of gestation compared with 
the growth patterns of hepatocellular carcinoma. 
pseudoglandular pattern, in other fields, trabeculae may grow together, compressing the 
sinusoids and forming sheets of tumor cells, producing a solid or compact pattern 
(Goodman ZD, 2007). Early hepatocellular carcinoma has a vaguely nodular appearance and 
is well differentiated. Progressed hepatocellular carcinoma has a distinctly nodular pattern 
and is mostly moderately differentiated, often with evidence of microvascular invasion 
(ICGHN, 2009). Small lesions with malignant potential show only subtle differences from 
the surrounding parenchyma, making them difficult to assess reproducibly. The 
International Working Party criteria of 1995 have led to remarkable progress in global 
standardization of nomenclature of liver nodules (International Working Party, 1995). 
However, although these criteria have been widely adopted, their application is challenging 
in equivocal lesions. Perhaps the most significant problem is that most histologic criteria are 
arrayed on a gradual spectrum and cannot be easily summarized as “present or absent”. 
Additionally, the number of criteria suggested in the literature are too numerous to achieve 
interobserver consensus, and the diagnostic weight carried by each of these criteria is 
uncertain. Frequently, criteria used for malignancy in other tissues, such as mitotic activity 
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and cellular atypia, are not represented to a significant degree in well differentiated 
hepatocellular carcinoma. In addition, the liver lacks a layered structure as seen in the 
gastrointestinal tract, it is difficult to determine the presence of destructive growth in early 
hepatocellular carcinomas. Despite these difficulties, current histologic criteria for these 
nodules clearly yield reliable diagnoses at both ends of the spectrum; most pathologists will 
correctly identify nodules up to low grade dysplastic nodule as benign, whereas even small 
well differentiated hepatocellular carcioma with distinct nodular pattern or small 
moderately differentiated hepatocellular carcinomas will be correctly identified as 
malignant. The remaining gray zone includes high grade dysplastic nodule and early 
hepatocellular carcinoma. In evaluation of these lesions, the presence of stromal invasion is 
a useful criterion of malignancy. Accordingly, pathologists can decide whether the 
equivocal tumor is hepatocellular carcinoma or high grade dysplastic nodule by recognizing 
the presence or absence of tumor cell invasion into the intratumoral portal tracts. When 
obvious stromal invasion is not found in an equivocal tumor, the lesion may be diagnosed 
as either high grade dysplastic nodules or early hepatocellular carcinomas without 
detectable invasion (ICGHN, 2009). The diagnosis of stromal invasion is subjective and may 
require the assistance of histochemical (Victoria Blue or reticulin stains) and 
immunohistochemical stains (keratin 7 or 19) for differentiation from pseudoinvasion (Park 
YN, 1998).  Biopsy diagnosis of equivocal nodules remains a challenge, because minute 
biopsy specimens may not contain intratumoral portal tracts, thus precluding the detection 
of stromal invasion. Similarly, the detection of unpaired arteries, mitoses, and various 
immunohistochemical markers are prone to sampling error (Senes G, 2007). Connective 
tissue stroma is typically sparse, and reticulin fibers are absent or reduced, being found only 
at the periphery of trabeculae. In contrast to most other malignant epithelial neoplasms, 
hepatocellular carcinoma is soft and the lack of a desmoplastic stroma is a helpful diagnostic 
clue (Goodman ZD, 2007). A subset of tumors, that has been named fibrolamellar 
epatocellular carcinoma, differs from other types of hepatocellular carcinoma in clinical 
features and prognosis (Craig JR, 1980)(Soreide O, 1986). Fibrolamellar carcinoma is a 
unique type of liver carcinoma that arises in non-cirrhotic livers of young individuals 
(Torbenson M, 2007). Its etiology is unknown. Histologically, the tumor is made up of large 
polygonal cells characterized by abundant granular eosinophilic cytoplasm, large 
vesiculated nuclei, prominent nucleoli and abundant stroma composed of lamellae of 
collagen. Lamellar bands of fibrosis are present within the tumor and can be seen in both 
primary and metastatic tumors (Ross HM, 2011). Rarely, hepatocellular carcinoma will 
produce abundant stroma, producing the scirrhous pattern of hepatocellular carcinoma 
(Goodman ZD, 2007). 
3. Immunohistochemistry 
Immunostains can be used to study hepatocellular carcinoma and to distinguish 
hepatocellular carcinoma from other focal lesion or other malignancies, especially 
intrahepatic cholangiocarcinoma and metastatic adenocarcinoma (Ishak KG, 2001)(Varma V, 
2004). As the cells of hepatocellular cacinoma attempt to mimic normal liver cells, they may 
produce any of the cellular products that can be found in hepatocytes both in health and in 
disease, and, if present, these are readily demonstrated by immunostaining. Unfortunately, 
they are not specific and many of these can also be found in tumors other than 
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hepatocellular carcinoma (Goodman ZD, 2007). There are no stains that can absolutely 
distinguish well-differentiated hepatocellular carcinoma from hepatic benign lesions, such 
as hepatocellular adenoma or dysplastic nodules, and similarly, no single stain can always 
distinguish poorly differentiated hepatocellular carcinoma from poorly differentiated 
cholangiocarcinoma or metastatic adenocarcinoma. However, selected immunostains, taken 
in the context of other morphologic features, can be very helpful in establishing the 
diagnosis of hepatocellular carcinoma in difficult cases.  
The polyclonal antiserum to carcinoembryonic antigen (pCEA) is useful in demonstrating 
bile canaliculi (fig. 2), both in normal liver and in hepatocellular carcinoma, due to the 
presence of a CEA-like cross-reactive substance called biliary glycoprotein I (Saad RS, 
2004)(Goodman ZD, 2007) (Onofre AS, 2007) (Lau SK, 2002). 
 
pCEA reactivity 
 
Hep-Par 1 granular pattern reactivity. 
Fig. 2. Immunohistochemistry for pCEA and Hep-Par 1. 
HepPar-1 (Hepatocyte Paraffin 1) is a monoclonal antibody that reacts with an epitope of 
liver mitochondria, with a typical granular pattern (fig. 2) in most liver specimens (Lugli A, 
2004)(Minervini MI, 1997) (Leong AS , 1998) (Zimmerman , 2001). It also sometimes reacts 
with other normal or pathological structure, such as renal tubules and intestinal epithelium 
as well as with intestinal metaplasia in the stomach and esophagus (Goodman ZD, 2007). It 
produces positive staining in the vast majority of cases of hepatocellularr carcinoma (Saad 
RS, 2004)(Siddiqui MT, 2002) and only a small percentage of other tumors, including some 
cholangiocarcinomas and metastatic adenocarcinomas from the stomach and other sites 
(Terracciano LM, 2003), but when used in the context of morphology, clinical setting and 
other stains, HepPar-1 is very useful in distinguishing hepatocelluar carcinoma from 
other malignancies (Wang L, 2006). The scientific literature reported cases of 
hepatocellular carcinoma negative for HepPar-1 (Sugiki T, 2004), probably due to the 
uneven distribution of HepPar-1 in hepatocellular carcinoma, as reported by our group 
(Senes G, 2007). What’s more the degree of positive staining could varies from case to case 
(Goodman ZD, 2007): some tumors have a very patchy distribution of positive cells, 
which can be easily missed in a small biopsy. 
Glypican 3 (GPC3), a cell-surface heparan sulfate proteoglycans that is secreted into the 
plasma, is a member of the glypican family of heparinsulfate proteoglycan linked to the cell 
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surface through a glycosylphosphatidylinositol anchor (Filmus J, 2001). Glypican 3 has been 
suggested to play a negative role in cell proliferation and an apoptosis-inducing role in 
specific tissues (Cano-Gauci DF, 1999). The gene is frequently methylated in various tumors 
and cell lines, suggesting a tumor-suppressive role in tumorigenesis (Di Tommaso, 2007). It 
is also overexpressed in hepatocellular carcinoma (Zhu ZW, 2001). Glypican-3 has recently 
become established as a serum and tissue marker for hepatocellular carcinoma, both at 
messenger and protein level (Capurro, 2003)(Libbrecht L  2006) (ICGHN, 2009). At the 
beginning, by using a home-made antibody, glypican 3 weak and focal staining was 
observed in hepatocellular carcinoma precursor lesions and a diffuse staining in the vast 
majority of hepatocellular carcinomas (Yamauchi N, 2005). Glypican-3  immunoreactivity 
has a reported sensitivity of 77% and specificity of 96% in the diagnosis of small 
hepatocellular carcinoma; therefore, glypican-3 positivity is a strong argument for 
malignancy but the absence of immunoreactivity does not help in the differential diagnosis 
(Libbrecht L  2006)(ICGHN, 2009). The staining pattern is usually cytoplasmic but may be 
membranous or canalicular. The monoclonal antibody from Biomosaics (IG12 clone) at a 
dilution of 1:50 to 1:100 as amplified with the new short polymer systems (Advance [Dako], 
Novolink [Novocastra], and Super-picture + [Zymed]) yields reliable results. Since glypican-
3 staining may be only focal, additional markers or a panel of markers may be necessary. 
Glypican-3 staining must be interpreted in context, because it may also be seen in 
regenerating hepatocytes in a setting of hepatitis and in melanocytic lesions (ICGHN, 
2009). A recent work from our group (Sollai M, 2011) sowed immunoreactivity for 
glypican-3 in the fetal human liver, caracterized by a strong immunostaning during the 
first month of gestation and by a progressive decrease, ending with a very weak 
expression at birth. This work may add new data to the theory of strict similarities 
between cell programs utilized during development, silenced at birth, and re-activated by 
tumor cells during liver cancerogenesis. 
HSP70 (heat shock protein 70) belongs to a class of genes (heat shock proteins) implicated in 
tumorigenesis, in the regulation of cell-cycle progression and apoptosis (Garrido C, 
2001)(Helmbrecht K, 2000)(ICGHN, 2009). Most hepatocellular carcinomas are associated 
with chronic inflammation and fibrosis, acting as stressful conditions that lead to heat shock 
protein synthesis. HSP70 is, in particular, a potent antiapoptotic survival factor (ICGHN, 
2009); it was reported as the most abundantly up-regulated gene among a set of 12,600 
genes in early hepatocellular carcinoma (Chuma et al, 2003). Furthermore, it was 
significantly overexpressed in progressed hepatocellular carcinoma as compared with early 
hepatocellular carcinoma, and in the latter as compared with precancerous lesions. HSP70 
immunoreactivity was recently reported in the majority of hepatocellular carcinomas, 
including early and well-differentiated forms, but not in non-malignant nodules (Di 
Tommaso L, 2007), thus suggesting its use as a marker of malignancy. HSP70 
immunoreactivity (SC-24 clone, dilution 1:250 to 1:500 amplified with short polymer 
systems; Santa Cruz Biotechnology, Santa Cruz, CA) is nucleocytoplasmic and mostly focal 
with 70% sensitivity for hepatocellular carcinoma detection in surgically resected specimens 
(Haussinger D, 1985).  
GS (glutamine synteatse) catalyzes the synthesis of glutamine from glutamate and ammonia 
in the mammalian liver (Haussinger D, 1985) where it has been shown to be restricted to 
hepatocytes surrounding the terminal hepatic venules in the murine and human liver 
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(Moorman AF, 1988, 1989). It is known that glutamine, the end product of glutamine 
synteatse activity, is the major energy source of tumor cells (Reitzer LJ, 1979). Based on 
findings on experimental hepatocarcinogenesis, GS positive tumor cells are believed to be 
derived from GS positive hepatocytes that have been affected by carcinogens. Thus, GS was 
suggested as a specific marker for tracing cell lineage relationships during 
hepatocarcinogenesis (Gebhardt R, 1999). Most importantly, GS is a target gene of β-catenin 
so that its overexpression is associated with mutations of β -catenin or with activation of this 
pathway (Christa et al, 1994)(ICGHN, 2009). Then up-regulation of GS mRNA, protein, and 
activity has been demonstrated in human hepatocellular carcinoma (Christa et al, 1994). 
Interestingly, a stepwise increase in GS immunoreactivity from precancerous lesions to early 
and to advanced hepatocellular carcinoma was also reported, proposing for GS a role in the 
promotion of the metastatic potential of hepatocellular carcinogenesis (Osada et al, 1999). 
The monoclonal antibody from Chemicon International (clone MB302) at a dilution of 1:500 
to 1:1000 and amplified with a new short polymer system yields reliable results. In order to 
increase its specificity as a marker of malignancy, GS immunostaining should be diffuse and 
strong, a pattern that can be seen in 50% of hepatocellular carcinomas, including early forms 
(Haussinger D, 1985). 
CHC (clathrin heavy chain) is an endothelial marker overexpressed in hepatocellular 
carcinoma (Seimiya M, 2008). CHC was chosen because it is an endothelial marker, it works 
well as an internal standard for non parenchymal liver cells and, as already suggested in a 
surgical series, is overexpressed in the cytoplasm of malignant hepatocytes (Seimiya M, 
2008). In contrast, most non malignant hepatocytes were reported to be negative or to have 
weak to moderate staining intensity (Seimiya M, 2008). 
Alpha-fetoprotein is frequently elevated in the serum of patients with hepatocellular 
carcinoma, even when the tumor is negative at immunostaining (Zhou L, 2006)(Wang L 
2006). In most published series, it has been found in less than an half of hepatocellular 
carcinomas: for that reason, it is less useful for diagnostic purposes (Goodman ZD, 2007) 
(Chu PG, 2002) (Onofre AS , 2007) (Lau SK , 2002).  
Cytokeratins are sometimes suggested as a means of tumor classification, especially 
cytokeratin 7 (Maeda , 1996)(Chu , 2000)(Durnez A et al 2006) and cytokeratin 20 (Chu P, 
2000) (Faa G , 1998), but in rare cases the tumor cells display aberrant keratin expression, 
suggesting that the staining pattern should be interpreted with caution (Fanni D, 2009). 
Cytokeratin 7 can be present in some hepatocelluar carcinomas, as well as cytokeratin 20, 
the latter in a minority of case. For that reason, cytokeratin 7 and 20 profiles are not very 
useful in the diagnosis of hepatocellular carcinoma (Goodman ZD, 2007). Cytokeratin 8-18 
(Porcell , 2000) (Van Eyken P, 1988), cytokeratin 19 (Maeda T, 1996)(Van Eyken P, 1988) as 
well as the staining with a pancytokeratin cocktail (AE1/AE3), that usually produces 
negative or weak staining, are less frequently used (Goodman ZD, 2007).  
CD34 is present and demonstrable in endothelial cells of large blood vessels and most 
capillary beds throughout the body, with the exception of normal hepatic sinusoidal 
endothelium. The trabeculae of hepatocellular carcinoma are surrounded by endothelial 
cells which phenotypically resemble capillary endothelium and are usually positive for 
CD34. On the contrary, normal hepatic sinusoidal endothelium and benign hepatocellular 
lesions typically have CD34 positive sinusoids only in areas that receive increased arterial 
www.intechopen.com
 Hepatocellular Carcinoma – Clinical Research 
 
72
blood: cirrhotic nodules tend to be positive only around the periphery of regenerative 
nodules and focal nodular hyperplasia may show immunoreactivity for CD34 restricted to 
the sinusoids bordering fibrous septa (Goodman ZD, 2007). A diffuse, regular CD34 
positivity of sinusoids can be helpful in distinguishing a cirrhotic nodule from a well-
differentiated hepatocellular carcinoma. The staining for CD34 in hepatocellular adenomas 
is variable: this means that caution should be taken in the interpretation of CD34 reactivity 
in well differentiated tumor lesions, because a positive stain does not necessarily indicate 
malignancy (Varma V 2004)(Gouysse G, 2004).  
CD68 is a transmembrane glycoprotein located within lysosomes and endosomes. Thus, 
macrophages as well as other cell types rich in lysosomes/endosomes are CD68-positive 
(Ross HM, 2011). The staining pattern of CD68 was explored in the epithelial cells of both 
fibrolamellar and typical hepatocellular carcinomas In the romer, CD68 reactivity was found 
in the majority of cases, whereas it was absent in classical hepatocellular carcinoma (Ross 
HM, 2011). 
4. Differential diagnosis 
The diagnosis of hepatocellular carcinoma is sometimes very straightforward, not requiring 
anything other than hematoxylin eosin stained sections, whereas in most cases it requires the 
proper evaluation of several fine histological features, the reticulin framework, and the type of 
neo-vascularization. Two types of benign lesions enter into the differential diagnosis of 
hepatocellular carcinoma: hepatocellular adenoma in a noncirrhotic liver, and dysplastic 
nodules in the setting of cirrhosis (Ishak KG, 2001)(International Working Party, 1995)(Theise 
ND, 2002). The most frequent problem is distinguishing poorly differentiated hepatocellular 
carcinoma from other malignancies, especially metastases but also from poorly differentiated 
cholangiocarcinoma. A large cell carcinoma with eosinophilic cytoplasm, prominent nuclei 
and nucleoli may well be hepatocellular but that diagnosis should not be made without 
definite evidence of hepatocellular differentiation. Bile, recognizable canaliculi on 
haematoxylin-eosin or CEA stain, a positive stain for alphafetoprotein, a granular staining 
pattern with HepPar-1, or a trabecular growth pattern allow a diagnosis of hepatocellular 
origin of tumor cells with more or less certainty. However, the very rare cases of liver 
metastasis from a gastrointestinal adenocarcinoma with hepatoid features should be excluded, 
particularly when no other evidence of hepatocellular differentiation is found (Porcell , 2000). 
The tumor could be metastatic than primary in the liver, especially in the absence of cirrhosis. 
Cholangiocarcinomas and metastatic adenocarcinomas typically have a desmoplastic stroma, 
in contrast to hepatocellular carcinoma. A tumor with abundant stroma is almost always an 
adenocarcinoma, with the exception of the rare fibrolamellar type and even rarer scirrhous 
type of hepatocellular carcinoma (Craig JR, 1980)(Soreide O, 1986). Other metastatic malignant 
tumors may also be confused with hepatocellular carcinoma, in particular those characterized 
by large tumor cells with abundant cytoplasm, including melanomas (especially amelanotic) 
carcinoids, some poorly differentiated neuroendocrine tumors and renal cell carcinomas.  
4.1 Hepatocellular carcinoma versus hepatocellular adenoma  
Hepatocellular adenoma typically develops in women in the reproductive age group, and is 
often associated with oral contraceptive steroid use. Microscopically, they are composed of 
benign-looking hepatocytes arranged in sheets and cords without acinar architecture. 
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Adenoma cells are usually larger and paler than nontumor hepatocytes of the surrounding 
liver, due to increased cytoplasmic glycogen and/or fat. The nuclei of the tumor cells are 
typically uniform and regular, the nuclear/cytoplasmic ratio is low, and mitoses are almost 
never seen (Tab. 1). A well-developed reticulin framework is usually present in the tumor 
(Goodman ZD, 2007). The sinusoids, with flattened endothelial lining cells, are usually 
compressed, thus contributing to the sheet-like appearance. Sometimes the sinusoids are 
dilated, a finding which can be mistaken for peliosis hepatis. Bile ducts are not found in 
hepatocellular adenoma, but ductules and progenitor cells may be present. The presence of 
dilated sinusoids and ductules has caused some tumors to be classified as a telangiectatic 
variant of focal nodular hyperplasia, but molecular studies have shown these to be a variant 
of hepatocellular adenoma (Paradis V, 2004).  
4.2 Hepatocellular carcinoma versus dysplastic nodule 
Dysplastic nodule is the term used for a benign lesion that can be confused with 
hepatocellular carcinoma (International Working Party, 1995)(Theise ND, 2002)(Hytiroglou 
P, 2004). These are nodules in a cirrhotic liver that are macroscopically distinct from the 
surrounding cirrhotic nodules. They are usually larger than surrounding nodules and may 
be detected by imaging studies. They may also differ in colour or texture and may bulge 
from the surface of the liver (Goodman ZD, 2007). Distinguishing a well-differentiated 
hepatocellular carcinoma from a regenerative nodule or from a dysplastic nodule may be 
very difficult, particularly in small needle aspiration or core biopsies (Libbrecht L  2006). 
Histological examination is required to distinguish a dysplastic nodule from a small 
hepatocellular carcinoma (Tab. 2), and they are further classified as low-grade or high-
grade, based on morphologic features (Goodman ZD, 2007).  
Low-grade dysplastic nodules  
Low-grade dysplastic nodules are sometimes vaguely nodular but are often distinct from 
the surrounding cirrhotic liver because of the presence of peripheral fibrous scar. This is not 
a true capsule, but rather condensation of scarring as is seen around all cirrhotic nodules 
(ICGHN, 2009). Architectural changes beyond clearly regenerative features are not present; 
these lesions do not contain pseudoglands or markedly thickened trabeculae. Unpaired 
arteries and portal areas are sometimes present in small numbers (Park YN, 1998). Nodule-
in-nodule lesions are not present. Low-grade dysplastic nodules are composed of liver cells 
that are minimally abnormal, showing mild increase in cell density with a monotonous 
pattern, and they have no cytologic atypia, though they may have large cell change, 
formerly referred to as large cell dysplasia and or atipia (Anthony PP, 1973). The 
nuclear/cytoplasmic ratio is normal or slightly increased and there are no mitoses. The large 
cell atipia is charcterized by slightly nuclear pleomorfism (aneuploidia), multinucleation, 
abundant cytoplasm, mixed with normal hepatocyte. Steatosis may be present and there 
may be Mallory bodies (Goodman ZD, 2007). Low-grade dysplastic nodules may have 
diffuse siderosis or diffusely increased copper retention (ICGHN, 2009). Iron may be 
increased or decreased compared to the surrounding cirrhotic liver (Goodman ZD, 2007). 
Among members of the consensus panels ICGHN, 2009 there was no serious difficulty in 
differentiating Low-grade dysplastic nodules from early hepatocellular carcinoma. At the 
opposite end of the spectrum, distinction between Low-grade dysplastic nodules and 
large regenerative nodules was often found to be difficult or impossible. Therefore, there 
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is currently consensus that distinction between these two diagnostic categories cannot be 
made confidently by morphology alone and remains a task for the future. Fortunately, 
this distinction does not appear to have significant practical consequences at present 
(ICGHN, 2009). 
High-grade dysplastic nodules  
High-grade dysplastic nodules may be distinctly or vaguely nodular in the background of 
cirrhosis, although they also lack a true capsule, similar to low-grade dysplastic nodules; 
however, they are more likely to show a vaguely nodular pattern than low-grade dysplastic 
nodules. An high-grade dysplastic nodules is defined as having architectural and/or 
cytologic atypia, but the atypia is insufficient for a diagnosis of hepatocellular carcinoma. 
These lesions most often show increased cell density, sometimes more than 2 times higher 
than the surrounding nontumoral liver, often with an irregular trabecular pattern (ICGHN, 
2009). Small cell change, also known as small cell dysplasia or atipia is the most frequently 
seen form of cytologic atypia in high-grade dysplastic nodules (Watanabe S, 1983). Small cell 
atipia refers to clusters of cells with features that suggest increased cellular proliferation. 
Hepatocytes show small or regular size, with hypercromic irregular nuclei, nuclear groove, 
anphophilic cytoplasm, nodular pattern, decreased reticolin small cell change. Plates more 
than two cells thick, pseudogland formation, cytoplasmic basophilia, higher 
nuclear/cytoplasmic ratio, nuclear hyperchromasia or an irregular nuclear contour are the 
most suggestive diagnostic elements (Goodman ZD, 2007). These features often confined to 
one or more foci within the nodule, giving the appearance ‘nodule-in-nodule’ formation 
(Goodman ZD 2007). This form of atypia may also occur in small hepatocellular foci outside 
of high-grade dysplastic nodules; the term dysplastic focus (International Working Party, 
1995) may be appropriately used for such lesions. Large cell change may or may not be 
present in high-grade dysplastic nodules. Unpaired arteries are found in most lesions, but 
usually not in great numbers. A nodule-in-nodule appearance is occasionally found in high-
grade dysplastic nodules, and subnodules often have a higher labeling index of proliferating 
cell nuclear antigen or Ki-67 than that of high-grade dysplastic nodules parenchyma. When 
a nodule with largely high-grade dysplastic features contains a subnodule of hepatocellular 
carcinoma, the subnodule of hepatocellular carcinoma is usually well-differentiated with a 
well-defined margin. The diagnostic discrepancy between high-grade dysplastic nodules 
and early hepatocellular carcinoma was frequent at the first consensus meeting, but it 
remarkably improved at the second meeting, due to the recognition of stromal invasion as a 
diagnostic criterion for the differentiation of high-grade dysplastic nodules from early 
hepatocellular carcinoma (ICGHN, 2009). If areas of questionable invasion are present, 
immunostaining for keratins 7 or 19 may be useful; if such stainings demonstrate a ductular 
reaction, the focus is considered a pseudoinvasion and does not warrant a diagnosis of 
hepatocellular carcinoma (Park YN, 2007). It is generally accepted that high-grade dysplastic 
nodule are precursors of hepatocellular carcinoma based on several lines of evidence, 
including morphologic features intermediate between low grade nodules and hepatocellular 
carcinoma, the presence of foci of hepatocellular carcinoma in otherwise high-grade 
dysplastic nodules, and follow-up showing progression to malignancy in a few cases. In 
some cases in clinical practice, it may be impossible to distinguish a high-grade dysplastic 
nodule from a well differentiated hepatocellular carcinoma, especially in needle biopsies. 
The current ability to increase the survival of patients with hepatocellular carcinoma relies 
upon the surveillance of cirrhotic patients. Surveillance allows hepatocellular carcinoma 
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precursors (dysplastic nodules) and malignant tumors to be recognized at an earlier stage 
making cure possible. Radiology plays a major role in hepatocellular carcinoma diagnosis 
because hepatocellular carcinoma is characterized by neoarterial vascularisation with a 
typical imaging pattern. Current international guidelines have restricted the use of the liver 
biopsy to the characterization of hepatocellular nodules which remain diagnostically 
equivocal after imaging. Thus pathologists are today facing very challenging and often well 
differentiated lesions, leading to difficulties in distinguishing high grade dysplasia and well 
differentiated hepatocellular carcinoma. In this scenario novel concepts obtained through 
international consensus have been proposed with emphasis on hepatocellular carcinoma of 
small size (up to 2 cm) which includes 2 distinct types, the early and progressed hepatocellular 
carcinoma (Roncalli M, 2011). High nuclear/cytoplasmic ratio of tumor cells is the most 
reliable sign of malignancy, even when the nuclei are not atypical, and this feathures, in 
combination with trabecular or pseudoglandular growth patterns distinguishes well-
differentiated hepatocellular carcinoma from benign hepatocellular lesions (Goodman ZD, 
2007).  One of the main features used in this distinction is stromal invasion, which is usually 
not present in needle biopsy material (Park YN, 2007). Sampling errors in the biopsies may 
significantly influence the final diagnosis. It is indeed these small and limited tissue samples 
that pathologists rely upon, to make real diagnoses. The differential diagnosis of small, well-
differentiated hepatocellular nodules mainly rests on fine histological criteria which can be 
difficult to adequately evaluate on tiny samples (Goodman ZD, 2007).  
Early or small well-differentiated hepatocellular carcinoma 
Early hepatocellular are vaguely nodular and are characterized by various combinations 
of the following major histologic features (Hytiroglou P, 2004)(Kojiro M, 2006)(Hytiroglou 
P, 2007): 
1. increased cell density more than 2 times that of the surrounding tissue, with an 
increased nuclear/cytoplasm ratio and irregular thin-trabecular pattern; 
2. varying numbers of portal tracts within the nodule (intratumoral portal tracts); 
3. pseudoglandular pattern;  
4. diffuse fatty change; and 
5. varying numbers of unpaired arteries. 
Among these features, diffuse fatty change is observed in approximately 40% of cases 
(Kutami R, 2000). The characteristic features of early hepatocellular carcinoma are 
sometimes seen in larger tumors. Including well-differentiated tumors that measure over 2 
cm and thus do not qualify for the designation of small hepatocellular carcinoma set forth 
by the IWP. The prevalence of fatty change decreases along with increasing tumor size; 
therefore, fatty change is uncommon in tumors larger than 3 cm. Fatty change is also 
uncommon in moderately differentiated hepatocellular carcinomas. Any of the features 
listed above may be diffuse throughout the lesion or may be restricted to an expansile 
subnodule (nodule-in-nodule). Most importantly, because all of these features may also be 
found in high dysplastic nodules, it is important to note that stromal invasion remains 
most helpful in differentiating early hepatocellular carcinoma from high dysplastic 
nodules (ICGHN, 2009). 
Pathologists today are asked to provide timely and conclusive diagnostic reports for the 
management and therapy of radiologically equivocal hepatocellular nodules found in small 
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biopsy samples. Although the traditional hematoxylin-eosin-based morphology remains the 
milestone, integration with biological information is required to make biopsy interpretation 
more objective and reproducible. To support the morphological criteria, additional and 
more objective criteria of malignancy, such as stromal invasion and the composite 
expression of a number of tissue biomarkers (translated to clinical practice from expression 
studies of human hepatocarcinogenesis (Chuma M, 2007)(Paradis V, 2003)(Nam SW, 
2005)(Llovet JM, 2006)(Wurmbach E, 2007)(Di Tommaso L, 2007), have been proposed. Some 
have already been validated, as recently emphasized by Roskams and Kojiro (Roskams T, 
2010), and their use in clinical practice has been suggested in the recent update of the 
AASLD practice guidelines (Bruix J, 2011). Indeed, the use of these tools can make 
pathologists, even those not specialized in liver pathology and in the diagnosis of liver 
tumor, more confident in the fine diagnostics of this challenging field. This is particularly 
true for small hepatocellular carcinoma, which is the most curable form and is particularly 
difficult to recognize with imaging. Non invasive imaging techniques were successful in 1- 
to 2 cm hepatocellular carcinoma detection in patients with cirrhosis in only 33% of cases 
(Forner A, 2008). In these cases the application of a panel of putative markers, such as 
glypican3, HSP70 and GS was thought to help to address the diagnostic challenge (Di 
Tommasi 2007). Hepatocelluar carcinoma is supported by the immunoreactivity of at least 2 
markers while lack of immunoreactivity does not conclusively rule out malignancy. When 
morphological features suggest a non-malignant nodule an immunonegative profile is 
expected. In these cases, the staining of 2 markers should prompt reconsideration of the 
diagnosis. The panel may also be useful in clinically obvious but tangentially or minimally 
sampled tumors. It should be noted that in this setting the sparse peripheral neoplastic cells 
that might have been insufficient for a conclusive diagnosis of malignancy on hematoxylin 
eosin can easily be highlighted by the panel (Di Tommasi, 2009). The endothelial marker 
clathrin heavy chain (CHC) has been recently suggested to be diagnostically useful as well, 
particularly in combination with GPC3 (Seimiya M, 2008); its value was initially tested in 
surgical specimens (Seimiya M, 2008), and really also in liver biopsy samples (Di Tommasi 
2011). A homogeneous series of small hepatocellular carcinoma no more then 2 cm in 
diameter and, for comparison, non small hepatocellular carcinomas sampled by a fine-
needle approach (20-21 gauge) were immunostained for CHC with the aim of determining 
whether the addition of a novel marker (CHC) to the previously validated panel could 
increase the panel’s diagnostic accuracy in the detection of small hepatocellular carcinoma 
(Di Tommasi 2011). The performance of the 4 markers’ panel was superior to the 
performance of the same panel without CHC (the 3 markers’ panel). With staining at least 
two markers, the accuracy was 97% and 84.3% in non small and small hepatocellular 
carcinomas, respectively, superior to the accuracy of the panel without the addition of CHC 
(86% and 76.9%, respectively). For small hepatocellular carcinomas, the addition of CHC to 
the panel consistently increased the sensitivity from 46.8% to 63.8%. Interestingly enough, 
for non small hepatocellular carcinomas, in cases in which the liver nodule was sampled 
with a 20 to 21 gauge needle, the accuracy of the novel panel (97%) was higher than the the 
previously reported (78.4%) with a 3M panel in an analogous hepatocellular carcinoma 
series sampled with 16- to 18-gauge needles. This means that the addition of CHC not only 
counterbalances the putative loss of sensitivity of thinner core materials but also increases 
the diagnostic accuracy. Although the use of a 4 markers’ panel is more elaborate and time-
consuming for pathologists, the unitary cost of an additional immunoreaction to the panel is 
much less expensive than confirmatory additional imaging (Sangiovanni A, 2010) or repeat 
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liver biopsies. When hepatocellular carcinoma series were dissected into subpopulations 
according not only to size but also to grading (G1 versus G2/G3), the panel accuracy 
remained excellent and greater than 90% for G2/G3 hepatocellular carcinomas, regardless of 
the size. This datum  confirms that the performance of the 4 markers’ panel is optimal when 
tumor differentiation is compromised; in other words, the individual markers of the panel 
cooperatively stain hepatocellular carcinomas that have progressed. Unfortunately, these 
are cases for which the pathological diagnosis can be rendered on morphological grounds 
without the use of staining beyond hematoxylin eosin. Interestingly, although the tumor 
size was not an issue in G2/G3 hepatocellular carcinomas, it was a major issue in well-
differentiated (G1) hepatocellular carcinomas. Indeed, in this hepatocellular carcinoma 
group, which is the most difficult to evaluate in routine clinical practice, the accuracy of the 
panel was still excellent in non small G1 hepatocellular carcinomas (93.9%) but dropped to 
67.4% in small G1 hepatocellular carcinomas. In the latter, the sensitivity for hepatocellular 
carcinoma detection was 50%, with 100% specificity, and the performance of the 4 markers’ 
panel was much better than that of the 3 markers’ panel. In addition, we noticed that a 
consistent fraction of these tumors showed negative staining (6/30, 20%) or one marker only 
(9/30, 30%). The most likely (though speculative) explanation for these conflicting results is 
that G1 hepatocellular carcinomas greater than 2 cm and G1 hepatocellular carcinomas 
smaller than 2 cm are not the same disease. An international agreement between Eastern 
and Western pathologists has recently been obtained for a new hepatocellular carcinoma 
entity: very well-differentiated, no more then 2 cm, hepatocellular carcinoma (which is also 
called very early hepatocellular carcinoma) (International Consensus Group for 
Hepatocellular Neoplasia, 2009). This is the earliest described and well-differentiated form 
of hepatocellular carcinoma and is likely the morphological link between high grade 
dysplastic nodule and hepatocellular carcinoma that has progressed. Very early 
hepatocellular carcinoma type is very difficult to recognize on imaging because of the 
immature vascular supply. A consistent fraction of the small G1 hepatocellular carcinoma 
cases likely belong to this very early type. The phenotypic profile of these cases is clearly 
distinct from that of other hepatocellular carcinomas of the present series, and this provides 
indirect proof of an earlier disease. Indeed, the small G1 hepatocellular carcinomas were less 
likely to be stained with the combination of the panel markers, their profile being 
intermediate between dysplasia (usually not staining) and hepatocellular carcinoma that has 
progressed (mostly staining). It is, therefore, reasonable to assume that when an 
hepatocellular carcinoma is just born, its phenotypic profile is not yet settled (e.g., the 
vascular support), and these markers are individually and progressively acquired and 
detectable. The most represented marker in small G1 hepatocellular carcinomas seemed to 
be CHC (58.8%), followed by GS (41.2%), HSP70 (17.6%), and GPC3 (11.8%). This means that 
in small G1 hepatocellular carcinomas, CHC is the most overexpressed marker. Thus, its 
evaluation, particularly in tumor core biopsy samples, is important, needs attention, and 
requires preliminary individual training. In particular, as for all the other markers under 
study, its staining should decorate putative malignant hepatocytes, and should appear as 
antigen overexpression in comparison with surrounding, adjacent nonneoplastic 
parenchymal cells. The prospective evaluation of nodules that remain diagnostically 
uncertain after biopsy could be very valuable for assessing the diagnostic strength of the 
present panel. Clearly, the search for additional and early markers has just started and is far 
less than completed. In conclusion, in core biopsy specimens of hepatocellular carcinomas 
sampled with a 20-to 21-gauge needle, the addition of CHC to a panel composed of GPC3, 
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HSP70, and GS increases the overall diagnostic accuracy in both small hepatocellular 
carcinomas (from 76.9% to 84.3%) and nonsmall hepatocellular carcinomas (from 86% to 97%), 
and there is an important gain in sensitivity in the detection of small hepatocellular carcinomas 
(from 46.8% to 63.8%). Absolute specificity was obtained only when two of the four markers 
were positive (regardless of which ones). Accuracy for hepatocellular carcinoma detection was 
not affected by the tumor size in G2/G3 hepatocellular carcinomas (>90%). In G1 
hepatocellular carcinomas, tumor size played a major role in discriminating cases, with higher 
accuracy for nonsmall hepatocellular carcinomas (93.9%) and lower accuracy for small 
hepatocellular carcinomas (67.4%); likewise, the sensitivity was 88.2% for nonsmall 
hepatocellular carcinomas and 50% for small hepatocellular carcinomas. This results suggest 
that small G1 hepatocellular carcinomas include early tumors characterized by a relatively 
silent phenotype and the progressive acquisition of the markers is under study. The use of the 
present panel of markers supports the recognition of both small and nonsmall HCCs in the 
diagnostic pathology of challenging cases sampled by core biopsy (Di Tommasi 2011). 
The combination of more than one putative marker of malignancy raises the overall 
accuracy. Glypican 3, HSP70 and GS have been found to be valuable in the differential 
diagnosis of hepatocellular carcinoma. A 3 markers’ panel composed by HSP70, GPC3, and 
GS was demonstrated to be very useful in distinguishing between dysplastic and early 
malignant hepatocellular nodules arising in cirrhosis (Di Tommaso, 2007, 2009). When 
applying a panel of these three markers (GPC3, HSP70, and GS) to resected small lesions, 
the finding of any two positive markers had a sensitivity of 72% and a specificity of 100% to 
detect malignancy (Di Tommaso 2007, 2009). The diagnostic accuracy of this 3 markers’ 
panel in liver biopsies of hepatocellular nodules has not been yet tested (ICGHN, 2009). 
Immunohistochemistry should not be use as a diagnostic tool without consideration for 
morphology; on the contrary, it should always be carefully considered and dictated by 
morphology, and should serve as an ancillary tool to support a diagnostic conclusion. 
Hepatocellular carcinoma is often characterized by marked morphological and phonotypical 
intratumoral variability. Senes et al (2006) observed a striking variability in the degree of 
differentiation of the tumor cells among the 17 different sub-nodules detected in a case of 
hepatocellular carcinoma. Moreover, even the expression of the immunohistochemical 
markers utilized in this study varied greatly among different tumor regions (Senes et al 
2006). As a consequence, in the case that, before the surgical resection, a needle biopsy had 
been performed, it was hypothesized that the interpretation of the bioptic core could have 
lead to different diagnoses, depending on the different tumor region sampled. This case 
underlines a previously unreported major role for sampling variability in the interpretation 
of needle biopsies and the possibility that, in clinical practice, when a very small fragment of 
the liver tumor is obtained by an ultrasound guided biopsy, immunoreactivity of the 
observed tumor cells could not sorely represent the distribution of tumor markers in the 
whole neoplasm, leading to sampling variability related diagnostic mistakes, not only for 
defining tumor grading but even in the differential diagnosis between primary and 
secondary liver tumor. 
4.3 Hepatocarcinoma versus other malignant neoplasia 
The differential diagnosis between hepatocellular carcinoma, cholangiocarcinoma and 
metastatic colorectal adenocarcinoma may be difficult when only based on morphology 
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(Terracciano , 2003). In fact, a subset of extrahepatic adenocarcinomas of different origin 
may show a solid “hepatoid” pattern virtually indistinguishable from hepatocellular 
carcinoma (Porcell , 2000). Similarly, metastases to the liver from various hepatoid variants 
of extra-hepatic neoplasms and other primary hepatic tumors, such as cholangiocarcinoma, 
may be mistaken for hepatocellular carcinoma (Varma V and Cohen C 2004). On the other 
hand, undifferentiated hepatocellular carcinoma may mimic poorly differentiated tumors of 
different origin, while its tubular and adenoid variants may be indistinguishable from 
cholangiocarcinoma or from metastatic colorectal adenocarcinoma. Furthermore, some of 
the unusual morphologic variants, including clear-cell, pleomorphic, and sarcomatoid 
variants, may be mistaken for metastases. The current literature shows that difficulties in 
histological typing of liver tumors, particularly in the differential diagnosis between 
hepatocellular carcinoma and cholangiocarcioma and metastases can be minimized by using 
immunohistochemistry (Varma V and Cohen C 2004)(Ma CK et al 1993). For that reason, in 
these cases, immunohistochemical analyses are often required (Stroescu , 2006). The panel of 
antibodies utilized to solve this differential diagnosis includes (tab. 2): cytokeratin 8-18 
(Porcell , 2000)(Van Eyken P, 1988)  Hep-Par1 (Leong AS , 1998) (Zimmerman , 2001) (Lugli 
A, 2004)(Minervini MI, 1997), glypican 3 (Yamauchi , 2005) (Libbrecht L  2006) (Zhu ZW et al 
2001) (Capurro M et al 2003), cytokeratin 7 (Maeda , 1996) (Chu , 2000) (Durnez A et al 2006), 
cytokeratin 20 (Chu P, 2000)(Faa G , 1998), cytokeratin 19 (Maeda T, 1996)(Van Eyken P, 
1988), CEA (Saad RS, 2004)(Goodman ZD, 2007) (Onofre AS , 2007) (Lau SK , 2002) and 
Alpha-fetoprotein (Onofre AS , 2007) (Lau SK , 2002) (Zhou L, 2006)(Wang L 2006). Among 
the numerous diagnostic immunohistochemical markers studied, alphafetoprotein (Wang L 
2006), cytokeratin 7 (Durnez A et al 2006), cytokeratin 20 (Chu P et al 2000), cytokeratin 19 
(Van Eyken P et al 1988), Hep-Par-1 (Zimmerman RL et al 2001)(Siddiqui MT et al 2002) and 
glypican 3 (Libbrecht L  2006) (Zhu ZW et al 2001) (Capurro M et al 2003) have been found 
to be the most valuable in the differential diagnosis between hepatocellular carcinoma and 
metastatic tumors. Immunoreactivity of tumour cells for cytokeratin 8-18, Hep-Par 1 and 
glypican 3 is considered suggestive of hepatocellular carcinoma; a diffuse immunoreactivity 
for cytokeratin 7 and cytokeratin 19 favours the diagnosis of cholangiocarcinoma; diffuse 
positivity for cytokeratin 20 and negativity for cytokeratin 7 are normally associated with 
metastatic colorectal adenocarcinoma. The sensitivity and specificity of the monoclonal 
antibody Hep-Par-1 for hepatocellular carcinoma are considered very high; as a 
consequence, the usefulness of this marker in the differential diagnosis of hepatic tumors 
is widely accepted (Chu PG et al 2002)(Saad RS et al 2004), although it stains normal 
hepatocytes as well. Moreover, expression profiling of primary hepatic tumors has 
demonstrated that glypican 3, a membrane-anchored heparan sulphate proteoglycan, is 
markedly expressed in hepatocellular carcinoma, particularly in well differentiated cases 
(Yamauchi N et al 2005). In spite of the availability of such armamentarium, daily 
experience shows that diagnostic mistakes can occur more frequently than generally 
expected. Indeed, some cases of hepatocellular carcinoma have been reported do not show 
immunoreactivity for Hep Par1 (Sugiki T et al 2004), nor for glypican 3 (Zhu ZW et al 
2001). We reported a case of hepatocellular carcinoma with a peculiar 
immunohistochemical profile, characterized by the association of the typical 
immunoreactivity of hepatocellular carcinoma with a diffuse and strong positivity for 
cytokeratin 20 (Fanni D, 2009), generally considered typical of metastatic colorectal 
adenocarcinoma. The reason for this heterogeneity in immunoreactivity of hepatocellular 
carcinomas could be related to multiple factors: different etiology, variable degree of 
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differentiation, size of the bioptic core and sampling variability (Maharaj B et al 1998).  
The differential diagnosis of these lesions is often difficult, especially because of the scant 
material obtained by needle biopsy (Zhu ZW et al 2001).  
5. Fibrolamellar carcinoma  
Despite the distinctive clinical and histological features of fibrolamellar carcinoma, this 
entity can be a diagnostic challenge, because of lack of consistency of the diagnosis of 
fibrolamellar carcinomas due by pathologists (Ross HM, 2011). Even among experts, weak 
reproducibility was seen in the histological diagnosis of primary liver tumors with fibrous 
stroma in non-cirrhotic patients and a consensus diagnosis was achieved in only 32% of the 
cases (Malouf G, 2009). A large difference is seen in the average age of diagnosis for cases of 
fibrolamellar carcinoma published in the peer reviewed literature versus cases diagnosed in 
the SEER database, a difference most likely explained by inconsistencies in making the 
diagnosis of fibrolamellar carcinoma (El-Serag HB, 2004). Histologically, a common 
diagnostic pitfall is the overinterpretation of intratumoral fibrosis as being diagnostic of 
fibrolamellar carcinoma. In addition, another common reason for misdiagnosis is a 
misperception that most cases of primary liver carcinoma in children and young adults are 
fibrolamellar carcinomas, leading to overdiagnosis of fibrolamellar carcinoma in this age 
group, especially with tumors arising in livers without underlying disease (Ross HM, 2011). 
To improve the reproducibility of the histological diagnosis, over the past several years 
immunohistochemical stains that may be of assistance have been searched. The role for 
immunohistochemical markers as an aide in the diagnosis of fibrolamellar carcinomas has 
been previously explored but sought for additional markers among the currently used panel 
of antibodies available in most hospital laboratories (Vivekanandan P, 2004)(Klein WM, 
2005). Fibrolamellar carcinomas show routinely strong immunoreactivity for CK7, while 
only about one third of typical hepatocellular carcinomas are CK7-positive (Klein WM, 
2005)(Abdul-Al HM, 2010)(Ward SC, 2010). Further analysis of previously reported gene 
expression  studies showed a modest increase in the expression of CD68 (Kannangai R, 
2007). The immunohistochemical profile of fibrolamellar carcinomas was further extended 
to include CD68 staining, because of the routine availability of CD68 in most hospital 
laboratories: this approach can be helpful in routine surgical practice. CD68 staining among 
cases from four different institutions have been shown that metastatic tumors do not lose 
their CD68 positivity (Ross HM, 2011). A distinctive pattern of immunostaining for CD68 in 
fibrolamellar carcinomas was demonstrated. Nearly all cases showed a granular, stippled 
pattern, or a dot-like pattern of positivity. This staining pattern is highly sensitive for 
fibrolamellar carcinoma, but is not specific. In terms of its possible role in routine clinical use, 
given its high negative predictive value, a diagnosis of fibrolamellar carcinoma in a primary 
liver carcinoma that is CD68 negative should be strongly re-considered to ensure that 
fibrolamellar carcinoma is the appropriate diagnosis (Ross HM, 2011). In addition to the 
fibrolamellar carcinomas, this distinctive pattern was also seen in a minority of conventional 
hepatocellular carcinoma in both of hepatocellular carcinomas arising in cirrhotic and non-
cirrhotic livers. Although not statistically significant, a larger percentage of conventional 
hepatocellular carcinomas that arose in non-cirrhotic livers showed CD68 staining. Whether 
this represents dysregulation of similar biological pathways is unclear. Also of note, CD68 
positivity was seen adjacent to necrosis and CD68 staining in this context should be 
interpreted cautiously. Another point that bears emphasis is that none of the cases in the 
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control groups that were CD68 positive had the typical histological features of fibrolamellar 
carcinoma. Thus, combining the histological findings with CD68 would likely increase the 
specificity of CD68 staining for fibrolamellar carcinoma. The reproducibility of the 
histological diagnosis of fibrolamellar carcinoma can be substantially improved by careful 
attention to the full pattern of histological features, including large polygonal tumor cells 
with abundant eosinophilic cytoplasm, large vesiculated nuclei, large nucleoli, and lamellar 
fibrosis (Torbenson M, 2007). Moreover, most cases should be CK7 positive (Klein WM, 
2005)(Abdul-Al HM, 2010)(Ward SC, 2010) as well as CD68 positive (Ross HM, 2011). In the 
absence of CK7 and/or CD68 positivity, a diagnosis of fibrolamellar carcinoma should be 
carefully re-considered. These findings also extend our understanding of the biology of  
 
Morphologica
l feature 
Hepatocellular 
carcinoma 
Hepatocellular 
adenoma  
Low grade 
dysplastic 
nodule 
High grade 
dysplastic 
nodule 
Cirrhosis 
background 
80% Absent 100% 100% 
Portal space Variable  Absent Present Present 
Bile duct Variable  Absent Present Present 
Isolated thick 
wall arteries 
Present  Present Rare Rare 
 
Architecture 
Tick trabecular, 
pseudo-glandular or  
solid pattern  
Sheet-like Regenerative 
feature 
Irregular 
trabecular 
pattern 
Nodularity Present  Not specific Absent Nodule in 
nodule 
Reticolin Absent Present Present Increased and 
irregular 
Cytological 
atipia 
Present Focal Absent Present 
N/C, nuclear 
pleomorphis
m 
Variable  Focal  Large cell 
dysplasia 
Small cell 
dysplasia 
Nucleoli Present  Absent  Absent Absent or small 
Steatosis Present  Present Absent Absent 
Mitoses Rare Absent  Absent Absent 
Stromal and 
vascular 
invasion 
Present  Absent  Absent Absent 
Ductular 
reaction (Ck7 
e Ck19) 
Variable Absent  Present Present 
CD34 Diffuse  Variable Variable Variable 
Ki67 High Low  Low  Variable  
Table 1. The morphological features that differentiate the hepatocellular carcinoma from 
hepatocellular adenoma and from dysplastic nodules. 
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fibrolamellar carcinomas. Their oncocytic appearance has typically been attributed to  
cytoplasmic swelling by numerous packed mitochondria, as seen in electron microscopy 
studies. The CD68 positivity indicates that fibrolamellar carcinomas also have increased 
lysosomal or endosomal accumulations in their cytoplasm, which may suggest that 
abnormalities in endosomal/lysosomal trafficking are characteristic of fibrolamellar 
carcinomas. Overexpression of CD68 protein occurs at the level of both mRNA and protein 
(Ross HM, 2010). Of note, one previous study examined a case of fibrolamellar carcinoma 
and found it to be CD68-positive when using clone KP1 but not clone PG-M1 (Kaiserling E, 
1995). They also reported that fibrolamellar carcinoma was weakly positive for Ki-M1P and 
3A5, and negative for an anti-lysozyme antibody (Kaiserling E, 1995). These authors also 
reported that the non-neoplastic liver in a case of biliary atresia was CD68 positive (using 
clone KP1) and that, based on electron microscopy, immunoreactivity correlated with 
lysosome-like granules as well as electron dense structures representing probably bile 
components. Thus, some caution is likely warranted when staining a tumor rich in 
cytoplasmic bilirubin for CD68, as the bilirubin may be stored in lysosomes within tumor 
cells. In sum, CD68 immunostaining is a sensitive marker for fibrolamellar carcinoma that 
may be of use in routine diagnostic surgical pathology. In addition, it may be of use in 
research studies by helping properly classify cases of fibrolamellar carcinoma. This is of 
importance because it can help ensure a uniform biological entity, being investigated by 
different groups, as the incorporation of non-fibrolamellar carcinoma cases in such studies is 
unlikely to improve our understanding of the biology of this disease.  
 
Immunohistochemical 
markers 
Hepatocellular 
carcinoma 
Cholangiocarcinoma Metastatic 
colorectal 
adenocarcinoma 
Alpha-fetoprotein  + - - 
pCEA + - - 
Hep-Par1 + - - 
Glypican 3 + - - 
Cytokeratin 8-18 + - - 
Cytokeratin 7 - + - 
Cytokeratin 19 - + - 
Cytokeratin 20 - -/+ + 
Table 2. The panel of immunohistochemistry that helps to solve the differential diagnosis 
between the hepatocellular carcinoma from other malignant neoplasms 
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